Latest news
Recce Pharmaceuticals Issues Cleansing Notice Following Share Issue - KalkineKalkine · Tue, 04 Aug 2026 07:04:52 GMTRecce Pharmaceuticals Files Cleansing Notice After Issuing 250,000 Shares on July 31, 2026 - Kalkine MediaKalkine Media · Tue, 04 Aug 2026 07:04:52 GMTRecce Pharmaceuticals Issues 250,000 Shares at $0.375 Each for Corporate Advisory Services - KalkineKalkine · Mon, 03 Aug 2026 00:42:42 GMTRecce welcomes US$66.9bn biodefence plan - The AustralianThe Australian · Fri, 31 Jul 2026 07:00:00 GMTSuperbug Fighter Recce Pharmaceuticals (ASX:RCE) Steps Into the Global Biodefence Spotlight - KalkineKalkine · Fri, 31 Jul 2026 07:00:00 GMTRecce Pharmaceuticals positioned for US$66.9 billion US biodefence strategy - Proactive InvestorsProactive Investors · Thu, 30 Jul 2026 01:40:00 GMTRecce Pharmaceuticals in Position to Benefit From US ASPR Medical Countermeasures Strategy - MoomooMoomoo · Wed, 29 Jul 2026 07:00:00 GMTRecce Pharmaceuticals (ASX:RCE) Advances Phase 3 Trials and MENA Licensing Strategy as Commercial Pathway Develops - KalkineKalkine · Tue, 28 Jul 2026 07:00:00 GMT